ClinicalTrials.gg
CompletedNCT06231043Updated Jan 30, 2024

Diclofenac IM Versus Tramadol IV in Acute Renal Colic, RCT

A Phase 4 interventional study of Diclofenac/Tramadol in Acute Renal Colic, sponsored by Lampang Hospital. Completed at 1 site in Thailand. Open to participants aged 18 Days and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Lampang Hospital · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Apr 2022, registered Jan 2024).
Phase
Phase 4
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Days and older
Sex
All
01

Study summary

Patients presented with acute pain from renal colic, the standard of care are prescribed NSAIDs, most common drug used is intramuscular (IM) Diclofenac injected at the gluteal muscle. Due to adverse effects in some patients, the nursing council has banned the injection by nurses. Since then, there has been a change in treatment by using intravascular (IV) Tramadol. According to various research, Diclofenac has a higher efficacy in controlling pain compared to other medications. In clinical practice, Tramadol has less efficacy of decreasing pain and a longer onset of action. At presence, there has been no research performed comparing the efficacy between these two drugs especially from the viewpoint of time dimension.

Read the detailed description

To compare the efficacy Diclofenac 75 mg IM versus Tramadol 50 mg IV in patients with acute pain from renal colic.

02

Conditions studied

  • Acute Renal Colic

Browse trials for

Keywords

  • Diclofenac IM versus Tramadol IV in acute renal colic, RCT
03

In context

Renal Colic

79 studies on the registry are indexed under Renal Colic; 10 are open to participants now.

This study's enrollment of 68 is below the median of 118 across 60 interventional studies indexed under Renal Colic.

Browse Renal Colic studies →

Lead sponsor

This is the only study on the registry with Lampang Hospital as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Days and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age over 18 years
  2. Acute pain in renal/ureteric colic
  3. Pain score more than 4
  4. Confirmation diagnosis by ultrasound bedside

Exclusion criteria

Exclusion Criteria:

  1. Refused to participate in the research
  2. Pregnancy
  3. of Diclofenac or Tramadol
  4. Urinary tract infection
  5. Skin infection at Buttock area
  6. Acute kidney injury
  7. CKD stage III, IV, V
  8. Bilateral severe hydronephrosis
  9. Physician refusal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Drug1

    Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.

    Drug: Diclofenac/Tramadol

  • Active comparator
    Drug2

    Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.

    Drug: Diclofenac/Tramadol

Interventions

  • DrugDiclofenac/Tramadol

    Drug pages: Diclofenac · Tramadol

    Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse. Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.

    Also known as: Fenac/Tramol

06

What researchers measure

Primary outcomes

  1. Diclofenac 75 mg IM or Tramadol 50 mg IV

    Time to pain relief

    Time frame: 30,60,90,120 minutes

07

Study locations

1 site
  • Lampang hospital
    Lampang, 52100, Thailand
08

References and documents

Individual participant data

Plan to share: No — Personal reasons

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Mar 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2024
First posted
Jan 30, 2024
StartActual
Apr 27, 2022
Primary completionActual
Mar 31, 2023
CompletionActual
Apr 15, 2023
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06231043
Lead sponsor
Lampang Hospital
Responsible party
JARUPA YAOWALAORNG (JARUPA YAOWALAORNG, Lampang Hospital) — Principal investigator
First posted
Jan 30, 2024
Start date
Apr 27, 2022
Primary completion
Mar 31, 2023
Completion
Apr 15, 2023
Last update
Jan 30, 2024

Study contacts

Jarupa Yaowalaorng
principal investigator · Lampang Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Diclofenac · Tramadol

Start the discussion